These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9581987)

  • 1. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.
    Mazzoran L; Tamaro G; Mangiarotti MA; Marchi P; Baracetti S; Gerini U; Fanni-Cannelles M; Zorat F; Pozzato G
    Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):125-31. PubMed ID: 9581987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
    Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
    Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
    Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T
    J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.
    Hiramatsu N; Hayashi N; Kasahara A; Hagiwara H; Takehara T; Haruna Y; Naito M; Fusamoto H; Kamada T
    J Hepatol; 1995 Feb; 22(2):135-42. PubMed ID: 7790701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
    Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagasawa M; Toyama T; Ozaki S; Naito M; Azuma M
    Hepatology; 1996 Jul; 24(1):27-31. PubMed ID: 8707274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase?
    Tsutsumi M; Takase S; Urashima S; Ueshima Y; Kawahara H; Takada A
    Alcohol Clin Exp Res; 1996 Dec; 20(9):1512-7. PubMed ID: 8986196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
    Nousbaum JB; Pol S; Nalpas B; Landais P; Berthelot P; Bréchot C
    Ann Intern Med; 1995 Feb; 122(3):161-8. PubMed ID: 7810932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serum 7S collagen in various liver diseases.
    Yamada S; Suou T; Kawasaki H; Yoshikawa N
    Clin Biochem; 1992 Dec; 25(6):467-70. PubMed ID: 1335851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.
    Capra F; Casaril M; Gabrielli GB; Tognella P; Rizzi A; Dolci L; Colombari R; Mezzelani P; Corrocher R; De Sandre G
    J Hepatol; 1993 Apr; 18(1):112-8. PubMed ID: 8340603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.
    Hino K; Sainokami S; Shimoda K; Iino S; Wang Y; Okamoto H; Miyakawa Y; Mayumi M
    J Med Virol; 1994 Mar; 42(3):299-305. PubMed ID: 7516422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
    Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
    Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
    Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
    J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
    J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.
    Lau JY; Davis GL; Kniffen J; Qian KP; Urdea MS; Chan CS; Mizokami M; Neuwald PD; Wilber JC
    Lancet; 1993 Jun; 341(8859):1501-4. PubMed ID: 8099380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease.
    Yamada M; Fukuda Y; Nakano I; Katano Y; Takamatsu J; Hayakawa T
    Acta Haematol; 1998; 99(4):212-6. PubMed ID: 9644299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.
    Yoshikawa M; Fukui H; Kojima H; Yoshiji H; Sakamoto T; Imazu H; Nakanani T; Matsumura Y; Kuriyama S; Yamao J
    J Gastroenterol; 1995 Jun; 30(3):367-71. PubMed ID: 7647904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate therapy and liver fibrosis: are human prolyl hydroxylase and type IV collagen reliable and sensitive markers?
    Tamaro G; Danek GM; Mangiarotti MA; Tamaro P; Zanazzo GA
    Int J Clin Lab Res; 1995; 25(1):55. PubMed ID: 7787212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.